Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
Australia
Annual Reports
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 17-ethoxycarbonyloxy-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylate, Chloromethyl
2. Alrex
3. Cehoac
4. Chloromethyl 17 Ethoxycarbonyloxy 11 Hydroxy 3 Oxoandrosta 1,4 Diene 17 Carboxylate
5. Chloromethyl 17-ethoxycarbonyloxy-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylate
6. Etabonate, Loteprednol
7. Lotemax
8. Loteprednol
1. 82034-46-6
2. Lotemax
3. Alrex
4. Hgp-1
5. Inveltys
6. Cddd-5604
7. P-5604
8. Cddd 5604
9. Chloromethyl (8s,9s,10r,11s,13s,14s,17r)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-17-carboxylate
10. Chebi:31784
11. Yeh1ez96k6
12. Kpi-121
13. Dsstox_cid_26468
14. Dsstox_rid_81641
15. Dsstox_gsid_46468
16. (11b,17a)-17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-androsta-1,4-diene-17-carboxylic Acid Chloromethyl Ester
17. Chloromethyl 17alpha-[(ethoxycarbonyl)oxy]-11beta-hydroxy-3-oxoandrosta-1,4-diene-17beta-carboxylate
18. Loterox
19. Locort
20. Lotemax (tn)
21. Cas-82034-46-6
22. Unii-yeh1ez96k6
23. Hgp 1
24. Loteprednol Etabonate [usan]
25. Airex
26. Loteprednol Etabonate (jan/usan)
27. Loteprednoletabonate
28. Ncgc00164594-01
29. Idr-90102
30. Idr-90103
31. Eysuvis
32. Loteprednol Etabonate Opphthalmic Suspension
33. P 5604
34. Schembl23907
35. Mls001424221
36. Gtpl7085
37. Chembl1200865
38. Dtxsid2046468
39. Hms2051f16
40. Hms2232j09
41. Hms3715n06
42. Loteprednol Etabonate [mi]
43. Loteprednol Etabonate [usan:jan]
44. Loteprednol Etabonate [jan]
45. Bcp28645
46. Zinc3920673
47. Tox21_112219
48. Bdbm50248301
49. Loteprednol Etabonate [vandf]
50. Mfcd00870765
51. S1669
52. Loteprednol Etabonate [mart.]
53. Akos005145741
54. Loteprednol Etabonate [who-dd]
55. Tox21_112219_1
56. Ccg-101041
57. Cs-0900
58. Db14596
59. Gs-3599
60. Nc00291
61. Loteprednol Etabonate, >=98% (hplc)
62. Ncgc00164594-02
63. Chloromethyl 11beta,17-dihydroxy-3-oxoandrosta-1,4-diene-17beta-carboxylate, 17-(ethyl Carbonate)
64. Hy-17358
65. Smr000469178
66. Loteprednol Etabonate [orange Book]
67. Zylet Component Loteprednol Etabonate
68. L0327
69. D01689
70. Loteprednol Etabonate Component Of Zylet
71. Ab00698349-05
72. Ab00698349-07
73. Ab00698349_08
74. 034l466
75. Q3837481
76. Androsta-1,4-diene-17-carboxylic Acid, 17-((ethoxycarbonyl)oxy)-11-hydroxy-3-oxo-, Chloromethyl Ester, (11.beta.,17.alpha.)-
77. Androsta-1,4-diene-17-carboxylic Acid, 17-((ethoxycarbonyl)oxy)-11-hydroxy-3-oxo-, Chloromethyl Ester, (11beta,17alpha)-
78. Chloromethyl (1s,2r,10s,11s,14r,15s,17s)-14-[(ethoxycarbonyl)oxy]-17-hydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-14-carboxylate
79. Chloromethyl 11.beta.,17-dihydroxy-3-oxoandrosta-1,4-diene-17.beta.-carboxylate, 17-(ethyl Carbonate)
| Molecular Weight | 466.9 g/mol |
|---|---|
| Molecular Formula | C24H31ClO7 |
| XLogP3 | 3.9 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 7 |
| Exact Mass | 466.1758310 g/mol |
| Monoisotopic Mass | 466.1758310 g/mol |
| Topological Polar Surface Area | 99.1 Ų |
| Heavy Atom Count | 32 |
| Formal Charge | 0 |
| Complexity | 882 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 7 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 4 | |
|---|---|
| Drug Name | Alrex |
| Drug Label | ALREX (loteprednol etabonate ophthalmic suspension) contains a sterile, topical anti-inflammatory corticosteroid for ophthalmic use.Loteprednol etabonate is a white to off-white powder.Loteprednol etabonate is represented by the following structura... |
| Active Ingredient | Loteprednol etabonate |
| Dosage Form | Suspension/drops |
| Route | Ophthalmic |
| Strength | 0.2% |
| Market Status | Prescription |
| Company | Bausch And Lomb |
| 2 of 4 | |
|---|---|
| Drug Name | Lotemax |
| PubMed Health | Loteprednol (Into the eye) |
| Drug Classes | Ophthalmologic Agent |
| Drug Label | LOTEMAX (loteprednol etabonate ophthalmic suspension) contains a sterile, topical anti-inflammatory corticosteroid for ophthalmic use. Loteprednol etabonate is a white to off-white powder.Loteprednol etabonate is represented by the following struct... |
| Active Ingredient | Loteprednol etabonate |
| Dosage Form | Ointment; Gel; Suspension/drops |
| Route | Ophthalmic |
| Strength | 0.5% |
| Market Status | Prescription |
| Company | Bausch And Lomb |
| 3 of 4 | |
|---|---|
| Drug Name | Alrex |
| Drug Label | ALREX (loteprednol etabonate ophthalmic suspension) contains a sterile, topical anti-inflammatory corticosteroid for ophthalmic use.Loteprednol etabonate is a white to off-white powder.Loteprednol etabonate is represented by the following structura... |
| Active Ingredient | Loteprednol etabonate |
| Dosage Form | Suspension/drops |
| Route | Ophthalmic |
| Strength | 0.2% |
| Market Status | Prescription |
| Company | Bausch And Lomb |
| 4 of 4 | |
|---|---|
| Drug Name | Lotemax |
| PubMed Health | Loteprednol (Into the eye) |
| Drug Classes | Ophthalmologic Agent |
| Drug Label | LOTEMAX (loteprednol etabonate ophthalmic suspension) contains a sterile, topical anti-inflammatory corticosteroid for ophthalmic use. Loteprednol etabonate is a white to off-white powder.Loteprednol etabonate is represented by the following struct... |
| Active Ingredient | Loteprednol etabonate |
| Dosage Form | Ointment; Gel; Suspension/drops |
| Route | Ophthalmic |
| Strength | 0.5% |
| Market Status | Prescription |
| Company | Bausch And Lomb |
A number of prescription loteprednol etabonate ophthalmic products are specifically indicated for the treatment of post-operative inflammation and pain following ocular surgery.
FDA Label
Loteprednol etabonate (LE) belongs to a unique class of corticosteroids with potent anti-inflammatory effects designed to be active at the site of action. Animal studies have shown that LE has a binding affinity to steroid receptors that is 4.3 times greater than dexamethasone. This particular class of steroids consists of bioactive molecules whose in-vivo transformation to non-toxic substances can be predicted from their chemistry and knowledge of enzymatic pathways in the body. Cortienic acid is an inactive metabolite of hydrocortisone and analogs of cortienic acid are also devoid of corticosteroid activity. Specifically, LE is an ester derivative of one of these analogs, cortienic acid etabonate. In particular, LE possesses a metabolically labile 17 beta-chloromethyl ester function which was designed in order to be hydrolyzed to an inactive carboxylic acid moiety. This inactive metabolite is more hydrophilic and is thus readily eliminated from the body. LE also exhibits good ocular permeation properties and good skin permeation properties.
Anti-Allergic Agents
Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)
Absorption
Loteprednol etabonate (LE) demonstrates good ocular permeation properties as it is lipid soluble, allowing the agent to penetrate into cells with relative ease. Results from the ocular administration of loteprednol in normal, healthy volunteers have shown that there are low or undetectable concentrations of either unchanged material or its metabolite. Following twice-daily unilateral topical ocular dosing of LE for 14 days in healthy subjects, the plasma concentrations of loteprednol etabonate were below the limit of quantitation (1 ng/mL) at all time points. These finds suggest that limited, if any, systemic absorption of LE occurs.
Route of Elimination
Following systemic administration to rats, loteprednol etabonate is eliminated primarily via the biliary/faecal route, with most of the dose eliminated in the form of the metabolite, PJ-90.
Volume of Distribution
The only data available regarding the volume of distribution of loteprednol etabonate (LE) is the volume of distribution the agent demonstrated when administered to dogs - a value of 3.7 L/kg. It has been shown, however, that the topical ocular administration of LE distributes preferentially into the cellular components of blood.
Clearance
Loteprednol etabonate was slowly hydrolyzed in liver at clearance rates of 0.21 +/- 0.04 and 2.41 +/- 0.13 ml/h/kg in the liver and plasma, respectively.
Loteprednol etabonate (LE) is readily and extensively metabolized to two inactive metabolites, PJ-90 (1-cortienic acid) and PJ-91 (1-cortienic acid etabonate). Metabolism occurs locally in ocular tissues, and to the extent that loteprednol etabonate reaches the systemic circulation, likely the liver and other tissues into which it distributes. In particular, studies have demonstrated that LE (chloromethyl 17alpha-ethoxycarbonyloxy-11beta-hydroxy-3-oxoandrosta-1,4-diene) is rapidly hydrolyzed at the location of its 17beta-chloromethyl ester function by paraoxonase 1 in human plasma at the site of administration at the level of the affected eye tissue to the 17beta-carboxylate PJ-91 metabolite and PJ-90 metabolite. Both metabolites are considered inactive.
The terminal half-life of loteprednol etabonate as determined when administered intravenously at a dose of 5 mg/kg in the dog animal model is 2.8 hours.
Corticosteroids like loteprednol etabonate inhibit the inflammatory response to a variety of inciting agents and likely delay or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation that are commonly associated with inflammation. While glucocorticoids are known to bind to and activate the glucocorticoid receptor, the molecular mechanisms involved in glucocorticoid/glucocorticoid receptor-dependent modulation of inflammation are not clearly established. Moreover, corticosteroids are thought to inhibit prostaglandin production through several independent mechanisms. In particular, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. The use of LE subsequently treats post-operative inflammation and pain following ocular surgery by managing the prostaglandin release, recruitment and travel of neutrophils and macrophages, and production of other inflammatory mediators that are intrinsically associated with the physical trauma of surgery.
Zach System is committed to providing Highly Customized Solutions for all your Development Programs.
GDUFA
DMF Review : Reviewed
Rev. Date : 2024-10-16
Pay. Date : 2024-10-08
DMF Number : 11105
Submission : 1994-09-26
Status : Active
Type : II
NDC Package Code : 60269-287
Start Marketing Date : 1998-03-09
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Bashu Health Korea Co., Ltd.
Registration Date : 2008-05-07
Registration Number : 4063-1-ND
Manufacturer Name : Zach system
Manufacturer Address : Zone Industrielle La Croix Cadeau Avrille, 49240, France
| Available Reg Filing : ASMF |
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26937
Submission : 2013-03-05
Status : Active
Type : II
NDC Package Code : 46439-8743
Start Marketing Date : 2012-04-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
| Available Reg Filing : EU |
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Gonane has API manufacturing expertise in new-age Corticosteroids, Hormones and other pharma raw materials.
Aarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26249
Submission : 2012-07-26
Status : Active
Type : II
Date of Issue : 2025-08-22
Valid Till : 2028-08-21
Written Confirmation Number : WC-0099
Address of the Firm :
NDC Package Code : 15308-0722
Start Marketing Date : 2011-06-30
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Ace Biopharm Co., Ltd.
Registration Date : 2024-03-14
Registration Number : Su289-18-ND
Manufacturer Name : Aarti Pharmalabs Limited
Manufacturer Address : Plot No. E–50, 50/1 & 59/1, Unit-IV, MIDC, Tarapur, Taluka & District-Palghar, 401 506, Maharashtra State, India.
| Available Reg Filing : ASMF |
Bhavna Laboratories is an API & Intermediate manufacturer focusing on the muscle relaxant & ophthalmic segments.
Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-07-05
Pay. Date : 2023-01-24
DMF Number : 27717
Submission : 2013-11-11
Status : Active
Type : II
NDC Package Code : 46439-8744
Start Marketing Date : 2012-04-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
| Available Reg Filing : EU |
GDUFA
DMF Review : Reviewed
Rev. Date : 2024-12-05
Pay. Date : 2024-10-25
DMF Number : 38817
Submission : 2024-03-20
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Zach System is committed to providing Highly Customized Solutions for all your Development Programs.
GDUFA
DMF Review : Complete
Rev. Date : 2024-10-16
Pay. Date : 2024-10-08
DMF Number : 11105
Submission : 1994-09-26
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2023-07-05
Pay. Date : 2023-01-24
DMF Number : 27717
Submission : 2013-11-11
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26937
Submission : 2013-03-05
Status : Active
Type : II
Aarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26249
Submission : 2012-07-26
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 22278
Submission : 2008-12-02
Status : Inactive
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2024-12-05
Pay. Date : 2024-10-25
DMF Number : 38817
Submission : 2024-03-20
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2014-05-29
Pay. Date : 2014-03-20
DMF Number : 28031
Submission : 2014-03-07
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 11264
Submission : 1994-12-16
Status : Inactive
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2015-12-23
Pay. Date : 2015-04-03
DMF Number : 23672
Submission : 2010-04-01
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25435
Submission : 2011-12-06
Status : Inactive
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Aarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.
Date of Issue : 2025-08-22
Valid Till : 2028-08-21
Written Confirmation Number : WC-0099
Address of the Firm : Plot No.E-50, 50/1 and 59/1, Unit-IV, MIDC, Tarapur-401506, Taluka: Palghar, Dis...
Date of Issue : 2025-10-24
Valid Till : 2027-10-23
Written Confirmation Number : WC-0625
Address of the Firm : PLOT NO.: В-29/1, MIDC MAHAD, VILLAGE BIRWADI,MAHAD - 402301, Taluka: MAHAD, Di...

Date of Issue : 2024-11-05
Valid Till : 2027-11-04
Written Confirmation Number : WC-0485
Address of the Firm : Block No. 203, Vaso-Alindra Road, PO Alindra-387510, Tal-Matar Dist. Kheda, Guja...

Date of Issue : 2022-08-08
Valid Till : 2025-07-14
Written Confirmation Number : WC-0168
Address of the Firm : Plot No. 24/2, & 25, Phase -IV, GIDC Industrial Zone, At & Post - Panoli, Dist.-...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Zach System is committed to providing Highly Customized Solutions for all your Development Programs.
Registrant Name : Bashu Health Korea Co., Ltd.
Registration Date : 2008-05-07
Registration Number : 4063-1-ND
Manufacturer Name : Zach system
Manufacturer Address : Zone Industrielle La Croix Cadeau Avrille, 49240, France
Aarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.
Registrant Name : Ace Biopharm Co., Ltd.
Registration Date : 2024-03-14
Registration Number : Su289-18-ND
Manufacturer Name : Aarti Pharmalabs Limited
Manufacturer Address : Plot No. E–50, 50/1 & 59/1, Unit-IV, MIDC, Tarapur, Taluka & District-Palghar, 401 ...
Registrant Name : HL Genomics Co., Ltd.
Registration Date : 2016-04-04
Registration Number : 94-3-ND
Manufacturer Name : HL Genomics Co., Ltd. @[Star...
Manufacturer Address : 1552 Bogaewonsam-ro, Wonsam-myeon, Cheoin-gu, Yongin-si, Gyeonggi-do @ [Starting mate...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Zach System is committed to providing Highly Customized Solutions for all your Development Programs.
NDC Package Code : 60269-287
Start Marketing Date : 1998-03-09
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 46439-8744
Start Marketing Date : 2012-04-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 46439-8743
Start Marketing Date : 2012-04-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
Aarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.
NDC Package Code : 15308-0722
Start Marketing Date : 2011-06-30
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 65089-0037
Start Marketing Date : 1998-03-09
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 63190-0780
Start Marketing Date : 2012-09-28
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 55718-154
Start Marketing Date : 1998-09-03
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : DRUG FOR FURTHER PROCESSING

NDC Package Code : 55718-152
Start Marketing Date : 1998-03-09
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : DRUG FOR FURTHER PROCESSING

NDC Package Code : 55718-142
Start Marketing Date : 2004-12-14
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : DRUG FOR FURTHER PROCESSING

NDC Package Code : 55718-155
Start Marketing Date : 2012-10-12
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : DRUG FOR FURTHER PROCESSING

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Zach System is committed to providing Highly Customized Solutions for all your Development Programs.
About the Company : Zach System, a subsidiary of Zambon Company, provides Active Pharmaceutical Ingredients (APIs), intermediates, and custom synthesis services aligned with customer timelines and bud...
About the Company : Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-qual...
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for pharmaceutical and biotech industries. LGM also operates as a full-service CDMO, offering formulat...
About the Company : Emay Pharmaceuticals Pvt Ltd operates as the merchant export division of M/s. Bhavna Laboratories Pvt Ltd. The company is a GMP-approved API manufacturer with over three decades of...
Gonane has API manufacturing expertise in new-age Corticosteroids, Hormones and other pharma raw materials.
About the Company : Gonane Pharma is a contract pharmaceutical company based in Gujarat, India, specializing in the manufacturing and marketing of corticosteroids, hormones, antivirals, and oncology p...
Aarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.
About the Company : Aarti Pharmalabs is generic APIs & Intermediates manufacturing company & small molecule drug substance CDMO and the largest Indian manufacturer of Xanthine Derivatives (Caffeine, e...
Bhavna Laboratories is an API & Intermediate manufacturer focusing on the muscle relaxant & ophthalmic segments.
About the Company : Bhavna Laboratories Pvt. Ltd., founded in 1986, is an Indian manufacturer of APIs and intermediates. The company is approved by the FDA of India and holds cGMP certification for it...
Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.
About the Company : Willow Birch Pharma, Inc. is a premier supplier of bulk APIs to North American Compounding Pharmacies, sourcing from FDA registered and GMP manufacturers. With licenses in all 50 s...
About the Company : More than 35 years of dedication to quality, service and pursuit of excellence, CHEMO was founded by Hugo Sigman, M.D., and Silvia Gold, Biochemist, in Spain (Barcelona), in 1977, ...

About the Company : Established in 1991, SM Biomed is a joint venture company pioneering the manufacture of API (active pharmaceutical ingredients) products in Malaysia. Company has grown several fold...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Loteprednol Etabonate, a steroid targeting the glucocorticoid receptor, shows promise in treating steroid-responsive inflammatory ocular conditions.
Lead Product(s): Loteprednol Etabonate,Tobramycin
Therapeutic Area: Ophthalmology Brand Name: Zylet-Generic
Study Phase: Approved FDFProduct Type: Steroid
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 11, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Loteprednol Etabonate,Tobramycin
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Alembic Pharmaceuticals Gets USFDA Nod for Loteprednol Etabonate and Tobramycin Ophthalmic
Details : Loteprednol Etabonate, a steroid targeting the glucocorticoid receptor, shows promise in treating steroid-responsive inflammatory ocular conditions.
Product Name : Zylet-Generic
Product Type : Steroid
Upfront Cash : Inapplicable
December 11, 2025

Details:
Bromfenac Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Retinal Vein Occlusion.
Lead Product(s): Bromfenac Sodium,Loteprednol Etabonate
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Bausch & Lomb Incorporated
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 29, 2025

Lead Product(s) : Bromfenac Sodium,Loteprednol Etabonate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Bausch & Lomb Incorporated
Deal Size : Inapplicable
Deal Type : Inapplicable
Post-Intravitreal Injection Pain Comparison Using Eye Treatments
Details : Bromfenac Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Retinal Vein Occlusion.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 29, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Lotemax SM (loteprednol etabonate) is a corticosteroid indicated for the treatment of postoperative inflammation and pain following ocular surgery.
Lead Product(s): Loteprednol Etabonate,Inapplicable
Therapeutic Area: Neurology Brand Name: Lotemax SM-Generic
Study Phase: Approved FDFProduct Type: Steroid
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 10, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Loteprednol Etabonate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Gets USFDA Nod for Loteprednol Etabonate Ophthalmic Gel
Details : Lotemax SM (loteprednol etabonate) is a corticosteroid indicated for the treatment of postoperative inflammation and pain following ocular surgery.
Product Name : Lotemax SM-Generic
Product Type : Steroid
Upfront Cash : Inapplicable
July 10, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The acquisition will complement Alcon’s existing portfolio in the large and fast-growing dry eye category. EYSUVIS (Loteprednol Etabonate) will complement the Systane® family of eye drops which includes the recently launched Systane Preservative-Free formulations.
Lead Product(s): Loteprednol Etabonate,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Eysuvis
Study Phase: Approved FDFProduct Type: Steroid
Sponsor: Alcon Inc
Deal Size: Undisclosed Upfront Cash: $60.0 million
Deal Type: Acquisition May 23, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Loteprednol Etabonate,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Alcon Inc
Deal Size : Undisclosed
Deal Type : Acquisition
Alcon to Acquire EYSUVIS Adding to Its Ophthalmic Eye Drop Portfolio
Details : The acquisition will complement Alcon’s existing portfolio in the large and fast-growing dry eye category. EYSUVIS (Loteprednol Etabonate) will complement the Systane® family of eye drops which includes the recently launched Systane Preservative-Free ...
Product Name : Eysuvis
Product Type : Steroid
Upfront Cash : $60.0 million
May 23, 2022

Details:
Klarity CL is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dry Eye Syndromes.
Lead Product(s): Klarity CL,Cyclosporine,Loteprednol Etabonate
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 11, 2022

Lead Product(s) : Klarity CL,Cyclosporine,Loteprednol Etabonate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization
Details : Klarity CL is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dry Eye Syndromes.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 11, 2022

Details:
Loteprednol Etabonate is a Steroid drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Corneal Endothelial Dystrophy.
Lead Product(s): Loteprednol Etabonate,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Steroid
Sponsor: Kala Pharmaceuticals
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 29, 2021

Lead Product(s) : Loteprednol Etabonate,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Kala Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection
Details : Loteprednol Etabonate is a Steroid drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Corneal Endothelial Dystrophy.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
November 29, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Kala is marketing two approved ophthalmology products, EYSUVIS® for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease (“DED”), and INVELTYS® for the treatment of post-operative inflammation and pain following ocular surgery.
Lead Product(s): Loteprednol Etabonate,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Eysuvis
Study Phase: Approved FDFProduct Type: Steroid
Sponsor: Oxford Finance
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing May 12, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Loteprednol Etabonate,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Oxford Finance
Deal Size : Undisclosed
Deal Type : Financing
Oxford Finance Provides $125 Million Credit Facility to Kala Pharmaceuticals
Details : Kala is marketing two approved ophthalmology products, EYSUVIS® for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease (“DED”), and INVELTYS® for the treatment of post-operative inflammation and pain following o...
Product Name : Eysuvis
Product Type : Steroid
Upfront Cash : Undisclosed
May 12, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Loteprednol Etabonate Ophthalmic Gel, 0.5% is indicated for the treatment of post-operative inflammation and pain following ocular surgery.
Lead Product(s): Loteprednol Etabonate,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Steroid
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 11, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Loteprednol Etabonate,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Akorn Receives FDA Approval for Loteprednol Etabonate Ophthalmic Gel, 0.5%
Details : Loteprednol Etabonate Ophthalmic Gel, 0.5% is indicated for the treatment of post-operative inflammation and pain following ocular surgery.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
February 11, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The FDA granted approval to EYSUVIS based on results from four clinical trials, including three Phase 3 trials and one Phase 2 trial, that demonstrated significant improvements in both the signs and symptoms of dry eye disease.
Lead Product(s): Loteprednol Etabonate,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Eysuvis
Study Phase: Approved FDFProduct Type: Steroid
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 27, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Loteprednol Etabonate,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Kala Pharmaceuticals Announces FDA Approval of EYSUVIS™ for the Short-Term Treatment of the Sign...
Details : The FDA granted approval to EYSUVIS based on results from four clinical trials, including three Phase 3 trials and one Phase 2 trial, that demonstrated significant improvements in both the signs and symptoms of dry eye disease.
Product Name : Eysuvis
Product Type : Steroid
Upfront Cash : Inapplicable
October 27, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
STRIDE 3 trial of EYSUVIS met both of its primary symptom endpoints, demonstrating a statistically significant improvement in ocular discomfort severity in both ITT population.
Lead Product(s): Loteprednol Etabonate,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Eysuvis
Study Phase: Phase IIIProduct Type: Steroid
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 04, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Loteprednol Etabonate,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Kala Pharmaceuticals Resubmits New Drug Application for EYSUVIS™ for Dry Eye Disease
Details : STRIDE 3 trial of EYSUVIS met both of its primary symptom endpoints, demonstrating a statistically significant improvement in ocular discomfort severity in both ITT population.
Product Name : Eysuvis
Product Type : Steroid
Upfront Cash : Inapplicable
May 04, 2020

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : RX
Registration Country : USA
Brand Name : INVELTYS
Dosage Form : SUSPENSION/DROPS;OPHTHALMIC
Dosage Strength : 1%
Packaging :
Approval Date : 2018-08-22
Application Number : 210565
Regulatory Info : RX
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : RX
Registration Country : USA
Brand Name : EYSUVIS
Dosage Form : SUSPENSION/DROPS;OPHTHALMIC
Dosage Strength : 0.25%
Packaging :
Approval Date : 2020-10-26
Application Number : 210933
Regulatory Info : RX
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : RX
Registration Country : USA
Brand Name : LOTEMAX
Dosage Form : SUSPENSION/DROPS;OPHTHALMIC
Dosage Strength : 0.5%
Packaging :
Approval Date : 1998-03-09
Application Number : 20583
Regulatory Info : RX
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : RX
Registration Country : USA
Brand Name : ALREX
Dosage Form : SUSPENSION/DROPS;OPHTHALMIC
Dosage Strength : 0.2%
Packaging :
Approval Date : 1998-03-09
Application Number : 20803
Regulatory Info : RX
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : RX
Registration Country : USA
LOTEPREDNOL ETABONATE; TOBRAMYCIN
Brand Name : ZYLET
Dosage Form : SUSPENSION/DROPS;OPHTHALMIC
Dosage Strength : 0.5%;0.3%
Packaging :
Approval Date : 2004-12-14
Application Number : 50804
Regulatory Info : RX
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : RX
Registration Country : USA
Brand Name : LOTEMAX
Dosage Form : OINTMENT;OPHTHALMIC
Dosage Strength : 0.5%
Packaging :
Approval Date : 2011-04-15
Application Number : 200738
Regulatory Info : RX
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : RX
Registration Country : USA
Brand Name : LOTEMAX
Dosage Form : GEL;OPHTHALMIC
Dosage Strength : 0.5%
Packaging :
Approval Date : 2012-09-28
Application Number : 202872
Regulatory Info : RX
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : RX
Registration Country : USA
Brand Name : LOTEMAX SM
Dosage Form : GEL;OPHTHALMIC
Dosage Strength : 0.38%
Packaging :
Approval Date : 2019-02-22
Application Number : 208219
Regulatory Info : RX
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : DISCN
Registration Country : USA
Brand Name : LOTEMAX
Dosage Form : SUSPENSION/DROPS;OPHTHALMIC
Dosage Strength : 0.5%
Packaging :
Approval Date : 1998-03-09
Application Number : 20841
Regulatory Info : DISCN
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : RX
Registration Country : USA
Brand Name : LOTEPREDNOL ETABONATE
Dosage Form : SUSPENSION/DROPS;OPHTHALMIC
Dosage Strength : 0.5%
Packaging :
Approval Date : 2019-04-17
Application Number : 207609
Regulatory Info : RX
Registration Country : USA

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code :
Brand Name : INVELTYS
Dosage Form : SUSPENSION/DROPS;OPHTHALMIC
Dosage Strength : 1%
Approval Date : 2018-08-22
Application Number : 210565
RX/OTC/DISCN : RX
RLD : Yes
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code : AB
LOTEPREDNOL ETABONATE; TOBRAMYCIN
Brand Name : ZYLET
Dosage Form : SUSPENSION/DROPS;OPHTHALMIC
Dosage Strength : 0.5%;0.3%
Approval Date : 2004-12-14
Application Number : 50804
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AB

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code :
Brand Name : LOTEMAX
Dosage Form : OINTMENT;OPHTHALMIC
Dosage Strength : 0.5%
Approval Date : 2011-04-15
Application Number : 200738
RX/OTC/DISCN : RX
RLD : Yes
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code : AB
Brand Name : LOTEMAX
Dosage Form : GEL;OPHTHALMIC
Dosage Strength : 0.5%
Approval Date : 2012-09-28
Application Number : 202872
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AB

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code : AB
Brand Name : LOTEMAX SM
Dosage Form : GEL;OPHTHALMIC
Dosage Strength : 0.38%
Approval Date : 2019-02-22
Application Number : 208219
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AB

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
Brand Name : LOTEPREDNOL ETABONATE
Dosage Form : SUSPENSION/DROPS;OPHTHALMIC
Dosage Strength : 0.2%
Approval Date : 2023-12-26
Application Number : 215550
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
Brand Name : LOTEPREDNOL ETABONATE
Dosage Form : SUSPENSION/DROPS;OPHTHALMIC
Dosage Strength : 0.5%
Approval Date : 2024-04-24
Application Number : 215719
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
Brand Name : LOTEPREDNOL ETABONATE
Dosage Form : SUSPENSION/DROPS;OPHTHALMIC
Dosage Strength : 0.5%
Approval Date : 2025-01-29
Application Number : 215204
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
Brand Name : LOTEPREDNOL ETABONATE
Dosage Form : SUSPENSION/DROPS;OPHTHALMIC
Dosage Strength : 0.5%
Approval Date : 2019-04-17
Application Number : 207609
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
Brand Name : LOTEPREDNOL ETABONATE
Dosage Form : SUSPENSION/DROPS;OPHTHALMIC
Dosage Strength : 0.2%
Approval Date : 2023-04-12
Application Number : 215933
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Italy
Brand Name : Lotemax
Dosage Form :
Dosage Strength : Coll 5 Ml 0.5%
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Estonia
Brand Name : Lotemax
Dosage Form : Eye Drops
Dosage Strength : 0.0005
Packaging :
Approval Date :
Application Number :
Regulatory Info : Prescription
Registration Country : Estonia

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : ALREX
Dosage Form : SUSPENSION
Dosage Strength : 0.2%/W/V
Packaging : 5ML
Approval Date :
Application Number : 2320924
Regulatory Info : Prescription
Registration Country : Canada

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : LOTEMAX
Dosage Form : SUSPENSION
Dosage Strength : 0.5%/W/V
Packaging : 5ML/10ML
Approval Date :
Application Number : 2321114
Regulatory Info : Prescription
Registration Country : Canada

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : LOTEMAX OINTMENT
Dosage Form : OINTMENT
Dosage Strength : 0.5%/W/W
Packaging : 1/3.5G
Approval Date :
Application Number : 2421941
Regulatory Info : Prescription
Registration Country : Canada

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : LOTEMAX GEL
Dosage Form : GEL
Dosage Strength : 0.5%/W/W
Packaging : 5G IN 10ML BOTTLE
Approval Date :
Application Number : 2435853
Regulatory Info : Prescription
Registration Country : Canada

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Generic
Registration Country : South Africa
Brand Name : Lotemax Ophthalmic Gel
Dosage Form : OPG
Dosage Strength : 5mg/ml
Packaging : 5X1mg/ml
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : South Africa

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Generic
Registration Country : South Africa
Brand Name : Lotemax Co
Dosage Form : OPD
Dosage Strength : 5mg/ml
Packaging : 5X1mg/ml
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : South Africa

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Lotemax Ophthalmic Suspension
Dosage Form : OPD
Dosage Strength : 5mg/ml
Packaging : 5X1mg/ml
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Alrex
Dosage Form : OPD
Dosage Strength : 2mg/ml
Packaging : 5X1mg/ml
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : India
Brand Name : Loteprednol Etabonate
Dosage Form : Nasal Spray
Dosage Strength : 0.1%
Packaging : 1x10ml HDPE Bottle
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Packaging : 1x10ml HDPE Bottle
Regulatory Info :
Dosage : Nasal Spray
Dosage Strength : 0.1%
Brand Name : Loteprednol Etabonate
Approval Date :
Application Number :
Registration Country : India

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : India
Brand Name : Loteprednol Tabanate
Dosage Form : Nasal Spray
Dosage Strength : 0.1%
Packaging : 1x10ml HDPE Bottle
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Packaging : 1x10ml HDPE Bottle
Regulatory Info :
Dosage : Nasal Spray
Dosage Strength : 0.1%
Brand Name : Loteprednol Tabanate
Approval Date :
Application Number :
Registration Country : India

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Ophthalmic Ointment
Dosage Strength : 0.5%/W/W
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Packaging :
Regulatory Info :
Dosage : Ophthalmic Ointment
Dosage Strength : 0.5%/W/W
Brand Name :
Approval Date :
Application Number :
Registration Country : India

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Ophthalmic Suspension
Dosage Strength : 0.2%
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Packaging :
Regulatory Info :
Dosage : Ophthalmic Suspension
Dosage Strength : 0.2%
Brand Name :
Approval Date :
Application Number :
Registration Country : India

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Generic
Registration Country : India
Brand Name :
Dosage Form : Suspension
Dosage Strength : 0.5%
Packaging : 5/10/15ml
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : India

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Packaging : 5/10/15ml
Regulatory Info : Generic
Dosage : Suspension
Dosage Strength : 0.5%
Brand Name :
Approval Date :
Application Number :
Registration Country : India

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Argentina
Brand Name : Lotesoft
Dosage Form : Ophthalmic Suspension
Dosage Strength : 0.5%
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Argentina

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Packaging :
Regulatory Info :
Dosage : Ophthalmic Suspension
Dosage Strength : 0.5%
Brand Name : Lotesoft
Approval Date :
Application Number :
Registration Country : Argentina

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Dosage Form : Tablet
Grade : Oral
Dosage Form : Cream / Lotion / Ointment
Grade : Topical, Parenteral
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Dosage Form : Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Global Sales Information
Market Place
Reply
18 Oct 2021

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Patents & EXCLUSIVITIES
Patent Expiration Date : 2033-05-03
US Patent Number : 11219596
Drug Substance Claim :
Drug Product Claim :
Application Number : 210933
Patent Use Code : U-2985
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2033-05-03

Patent Expiration Date : 2033-05-03
US Patent Number : 9532955
Drug Substance Claim :
Drug Product Claim :
Application Number : 210933
Patent Use Code : U-2491
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2033-05-03

Patent Expiration Date : 2033-05-03
US Patent Number : 10646437
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 210565
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2033-05-03

Patent Expiration Date : 2033-05-03
US Patent Number : 11219597
Drug Substance Claim :
Drug Product Claim :
Application Number : 210565
Patent Use Code : U-3278
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2033-05-03

Patent Expiration Date : 2033-05-03
US Patent Number : 9737491
Drug Substance Claim :
Drug Product Claim :
Application Number : 210933
Patent Use Code : U-2492
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2033-05-03

Patent Expiration Date : 2033-05-03
US Patent Number : 9393213
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 210565
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2033-05-03

Patent Expiration Date : 2033-05-03
US Patent Number : 11219597
Drug Substance Claim :
Drug Product Claim :
Application Number : 210565
Patent Use Code : U-3279
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2033-05-03

Patent Expiration Date : 2033-05-03
US Patent Number : 9056057
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 210933
Patent Use Code : U-2491
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2033-05-03

Patent Expiration Date : 2033-05-03
US Patent Number : 10688045
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 210933
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2033-05-03

Patent Expiration Date : 2033-05-03
US Patent Number : 11596599
Drug Substance Claim :
Drug Product Claim :
Application Number : 210933
Patent Use Code : U-2985
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2033-05-03

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

LOTEPREDNOL ETABONATE; TOBRAMYCIN
Exclusivity Code : CGT
Exclusivity Expiration Date : 2026-07-14
Application Number : 217597
Product Number : 1
Exclusivity Details :

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Patent Expiration Date : 2014-10-21
Date Granted : 2002-10-01
Brand Name : ALREX
Patent Number : 2174550
Filing Date : 1994-10-21
Strength per Unit : 0.20%
Dosage Form : Suspension
Human Or VET : Human
Route of Administration : Ophthalmic
Patent Expiration Date : 2014-10-21
Date Granted : 2002-10-01

Patent Expiration Date : 2014-10-21
Date Granted : 2002-10-01
Brand Name : LOTEMAX
Patent Number : 2174550
Filing Date : 1994-10-12
Strength per Unit : 0.50%
Dosage Form : suspension
Human Or VET : Human
Route of Administration : ophthalmic
Patent Expiration Date : 2014-10-21
Date Granted : 2002-10-01

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
89
PharmaCompass offers a list of Loteprednol Etabonate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Loteprednol Etabonate manufacturer or Loteprednol Etabonate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Loteprednol Etabonate manufacturer or Loteprednol Etabonate supplier.
PharmaCompass also assists you with knowing the Loteprednol Etabonate API Price utilized in the formulation of products. Loteprednol Etabonate API Price is not always fixed or binding as the Loteprednol Etabonate Price is obtained through a variety of data sources. The Loteprednol Etabonate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A LOTEPREDNOL ESTABONATE manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of LOTEPREDNOL ESTABONATE, including repackagers and relabelers. The FDA regulates LOTEPREDNOL ESTABONATE manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. LOTEPREDNOL ESTABONATE API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of LOTEPREDNOL ESTABONATE manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A LOTEPREDNOL ESTABONATE supplier is an individual or a company that provides LOTEPREDNOL ESTABONATE active pharmaceutical ingredient (API) or LOTEPREDNOL ESTABONATE finished formulations upon request. The LOTEPREDNOL ESTABONATE suppliers may include LOTEPREDNOL ESTABONATE API manufacturers, exporters, distributors and traders.
click here to find a list of LOTEPREDNOL ESTABONATE suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A LOTEPREDNOL ESTABONATE DMF (Drug Master File) is a document detailing the whole manufacturing process of LOTEPREDNOL ESTABONATE active pharmaceutical ingredient (API) in detail. Different forms of LOTEPREDNOL ESTABONATE DMFs exist exist since differing nations have different regulations, such as LOTEPREDNOL ESTABONATE USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A LOTEPREDNOL ESTABONATE DMF submitted to regulatory agencies in the US is known as a USDMF. LOTEPREDNOL ESTABONATE USDMF includes data on LOTEPREDNOL ESTABONATE's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The LOTEPREDNOL ESTABONATE USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of LOTEPREDNOL ESTABONATE suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a LOTEPREDNOL ESTABONATE Drug Master File in Korea (LOTEPREDNOL ESTABONATE KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of LOTEPREDNOL ESTABONATE. The MFDS reviews the LOTEPREDNOL ESTABONATE KDMF as part of the drug registration process and uses the information provided in the LOTEPREDNOL ESTABONATE KDMF to evaluate the safety and efficacy of the drug.
After submitting a LOTEPREDNOL ESTABONATE KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their LOTEPREDNOL ESTABONATE API can apply through the Korea Drug Master File (KDMF).
click here to find a list of LOTEPREDNOL ESTABONATE suppliers with KDMF on PharmaCompass.
A LOTEPREDNOL ESTABONATE written confirmation (LOTEPREDNOL ESTABONATE WC) is an official document issued by a regulatory agency to a LOTEPREDNOL ESTABONATE manufacturer, verifying that the manufacturing facility of a LOTEPREDNOL ESTABONATE active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting LOTEPREDNOL ESTABONATE APIs or LOTEPREDNOL ESTABONATE finished pharmaceutical products to another nation, regulatory agencies frequently require a LOTEPREDNOL ESTABONATE WC (written confirmation) as part of the regulatory process.
click here to find a list of LOTEPREDNOL ESTABONATE suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing LOTEPREDNOL ESTABONATE as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for LOTEPREDNOL ESTABONATE API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture LOTEPREDNOL ESTABONATE as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain LOTEPREDNOL ESTABONATE and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a LOTEPREDNOL ESTABONATE NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of LOTEPREDNOL ESTABONATE suppliers with NDC on PharmaCompass.
LOTEPREDNOL ESTABONATE Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of LOTEPREDNOL ESTABONATE GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right LOTEPREDNOL ESTABONATE GMP manufacturer or LOTEPREDNOL ESTABONATE GMP API supplier for your needs.
A LOTEPREDNOL ESTABONATE CoA (Certificate of Analysis) is a formal document that attests to LOTEPREDNOL ESTABONATE's compliance with LOTEPREDNOL ESTABONATE specifications and serves as a tool for batch-level quality control.
LOTEPREDNOL ESTABONATE CoA mostly includes findings from lab analyses of a specific batch. For each LOTEPREDNOL ESTABONATE CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
LOTEPREDNOL ESTABONATE may be tested according to a variety of international standards, such as European Pharmacopoeia (LOTEPREDNOL ESTABONATE EP), LOTEPREDNOL ESTABONATE JP (Japanese Pharmacopeia) and the US Pharmacopoeia (LOTEPREDNOL ESTABONATE USP).